Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor

• Published in: BMJ open diabetes research & care 2020-08, Vol.8 (1), p.e001386
• Main Authors: Tveter, Kevin M, Villa-Rodriguez, Jose A, Cabales, Alrick J, Zhang, Li, Bawagan, Fiona G, Duran, Rocio M, Roopchand, Diana E
• Format: Article
• Language: English
• Subjects: Bile; Body composition; Diabetes; Diet; Feces; Gene expression; Glucose; Homeostasis; Metabolism; Metabolites; Microbiota; Obesity; Polyphenols; Rodents; Transcription factors; Variance analysis
• ISSN: 2052-4897; 2052-4897
• DOI: 10.1136/bmjdrc-2020-001386

IntroductionBile acid (BA) biotransformation by gut bacteria impacts BA profile and signaling to nuclear receptors, such as the farnesoid X receptor (FXR) regulating glucose metabolism. Altered BA-FXR signaling was therefore investigated as a potential mechanism linking polyphenol-induced gut bacterial changes and improved glucose metabolism.Research design and methodsDiabetic db/db were fed low-fat diet (LFD) or LFD supplemented with a proanthocyanidin-rich extract of grape polyphenols (LFD-GP) for 4 weeks. Metabolic phenotypes, serum BAs, gut microbiota composition, and gene expression markers relevant to gut barrier and glucose metabolism were assessed. Gut organoids were used to investigate effects of individual BAs on ileal FXR activity.ResultsCompared with LFD-fed controls, GP supplemented db/db mice showed improved glucose metabolism, decreased relative abundance of gut bacteria associated with production of secondary BAs (SBAs), and depleted serum levels of SBAs taurohyodeoxycholic acid (THDCA), ω-muricholic acid (ωMCA), and tauro-ω-muricholic acid (TωMCA). Serum levels of primary BAs (PBAs) increased, consistent with higher gene expression of PBA synthesis enzyme Cyp7a1. GP-induced BA changes associated with FXR inhibition as evidenced by reduced expression of FXR-responsive genes Shp, Fgf15, and Fabp6 in ileum tissue as well as hepatic Shp, which negatively regulates PBA synthesis. GP treatment did not affect expression of hepatic Fxr or expression of Abcb11, Slc51b, and Obp2a genes controlling BA transport. Ceramide biosynthesis genes Smpd3, Sptlc2, and Cers4 were decreased in liver and intestine suggesting lower tissue ceramides levels may contribute to improved glucose metabolism. THDCA, ωMCA, and TωMCA behaved as FXR agonists in ileal organoid experiments; therefore, their depletion in serum of GP-supplemented db/db and wild type (WT) mice was consistent with FXR inhibition.ConclusionThese data suggest that by altering the gut microbiota, GPs modify BA-FXR signaling pathways to promote glucoregulation.